Arcus Biosciences Inc (Arcus Biosciences) operates as a clinical-stage biopharmaceutical company focused on creating innovative cancer immunotherapies by leveraging underexploited biological opportunities. Its product pipeline includes AB928, a selective dual antagonist of the adenosine receptors known as A2aR and A2bR in combination with anti-PD-1 antibody (AB122) and chemotherapy is used for the treatment of metastatic triple-negative breast cancer or ovarian cancer and advanced malignancies; AB122, an anti-PD-1 antibody targeting cancer; AB154, an anti-TIGIT antibody; and AB680, a CD73 inhibitor against solid tumors. Arcus Biosciences is headquartered in Hayward, California, the US.
Headquarters
United States of America
Address
3928 Point Eden Way, Hayward, California, 94545-3719
Website
arcusbio.com
Telephone
1 510 6946200
No of Employees
577
Industry
Pharmaceuticals and Healthcare
Ticker Symbol & Exchange
RCUS (NYSE)
Revenue (2022)
$117.0M
4.5%
(2022 vs 2021)
EPS
XYZ
Net Income (2022)
XYZ
-15%
(2022 vs 2021)
Market Cap*
$1.5B
Net Profit Margin (2022)
XYZ
-10.1%
(2022 vs 2021)
* As of and is in US$
Arcus Biosciences Inc premium industry data and analytics
Products and Services
| Products |
|---|
| Pipeline |
| Domvanalimab : Non-Small Cell Lung Cancer |
| AB308: Advanced Solid and Hematologic Malignancies |
| XYZ |
| XYZ |
| XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2024 | Stake Sale | In January, the company sold an additional 13% stake to Gilead Sciences Inc. for US$320 million. |
| 2023 | Contracts/Agreements | In December, the company and Exelixis entered into a clinical trial collaboration for STELLAR-009. |
| 2023 | Contracts/Agreements | In May, the company and Gilead Sciences expanded their research collaboration to include therapies for the treatment of inflammatory diseases. |
Competitor Comparison
| Key Parameters | Arcus Biosciences Inc | Merck & Co Inc | Pfizer Inc | Novartis AG | AstraZeneca Plc |
|---|---|---|---|---|---|
| Headquarters | United States of America | United States of America | United States of America | Switzerland | United Kingdom |
| City | Hayward | Kenilworth | New York | Basel | Cambridge |
| State/Province | California | New Jersey | New York | - | England |
| No. of Employees | 577 | 72,000 | 88,000 | 76,057 | 89,900 |
| Entity Type | Public | Public | Public | Public | Public |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Terry Rosen | Chief Executive Officer; Chairman | Executive Board | 2017 | 64 |
| Jennifer Jarrett | Chief Operating Officer; Director | Executive Board | 2020 | 52 |
| Juan Carlos Jaen | Director; President | Executive Board | 2015 | 65 |
| Bob Goeltz | Chief Financial Officer | Senior Management | 2020 | - |
| Dimitry Nuyten, M.D., Ph.D | Chief Medical Officer | Senior Management | 2022 | 47 |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward